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Objective: To determine whether puriﬁ  ed herbal extract of Salvia miltiorrhiza can improve the 
amniotic ﬂ  uid volume in pre-term oligohydramnios by improving uteroplacental circulation.
Methods: Forty-three pregnant women with oligohydramnios received a daily intravenous 
dose of 30 mL of salvia extract mixed with 5% glucose 500 mL. A control group of 41 women 
received daily 5% glucose 500 mL only. The amniotic ﬂ  uid index (AFI) was assessed at least 
twice a week by ultrasonographists who were blinded to the treatment. Both women and fetuses 
were monitored closely. The change in AFI was calculated and compared by paired t test within 
and between groups. The revised recommendations for improving the quality of reports of 
parallel group randomized trials were used.
Results: After a mean of 7.2 ± 2.7 days’ therapy, ranging from 3 to 18 days, the AFI increased 
signiﬁ  cantly from a mean of 4.9 ± 2.3 cm to a mean of 7.12 ± 2.36 cm, by a mean of AFI 0.18 ± 
0.06 cm/day (paired t = 3.62, p   0.005). In the control group, the AFI increased from a mean of 
5.1 ± 2.4 cm to a mean of 5.5 ± 3.1 cm after a mean of 6.1 ± 3.3 days’ treatment, ranging from 
4 to 15 days. The effect of salvia treatment on AFI in the salvia group was signiﬁ  cantly greater 
than in the control group (p   0.001). No side effects were observed in treated patients.
Conclusion: Salvia miltiorrhiza is an effective Chinese medicine for the treatment of oligo-
hydramnios.
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Introduction
Oligohydramnios, deﬁ  ned as an amniotic ﬂ  uid index (AFI) of less than the 5th percentile 
(at term  5 cm, or at pre-term  8.0 cm), has an incidence of 8.5% to 15.5% (Rutherford 
et al 1987; Sarno et al 1989; Moor et al 1990), and is associated with an increased risk 
of umbilical cord occlusion, fetal distress in labor, operative deliveries, and stillbirth 
at term. However, oligohydramnios observed in the second trimester or the early third 
trimester is particularly ominous, with perinatal mortality rates approaching 80%–90% 
(Baess et al 1984; Mercwe et al 1986). When amniotic ﬂ  uid is absent, the perinatal 
loss rate increases to 90% (Moore et al 1989). As shown earlier, oligohydramnios is 
a result of a decrease in fetal urine production and excretion with intact membranes 
and without fetal renal anomalies. The cause of the decrease in fetal urine production 
and excretion is chronic hypoxia because of placental dysfunction, resulting in shunt-
ing of fetal blood ﬂ  ow from the kidneys and a decrease in glomerular ﬁ  ltration rate. 
Therefore, oligohydramnios is usually accompanied by fetal growth restriction.
An effective medical therapy for oligohydramnios is very important for the fetus 
to grow normally to near term. Though some treatment modalities such as trans-
abdominal amniocentesis and maternal hydration have been suggested, none work 
well or resolve the primary cause.
In China, salvia, a kind of traditional Chinese herbal medicine extracted from Salvia 
miltiorrhiza, has been used to treat cardiovascular disease and promote microcirculation Therapeutics and Clinical Risk Management 2008:4(1) 288
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in microthrombosis for several decades (Zhang et al 2005). 
In this study, we used salvia to improve maternal blood 
circulation and enhance placental function, and observed its 
effect on amniotic ﬂ  uid volume.
Methods
The study protocol was approved by the local Institute Review 
Board and the hospital ethics committee. The puriﬁ  ed Salvia 
miltiorrhiza extract (PSME) was obtained from ZDQCB 
Corporation Ltd (Zhengjiang zhengda Qingchunbao Yao Ye, 
Zhengjiang, China, Batch No. 0503087, Z33020177).
After the patients had provided written informed consent, 
they were admitted to hospital and randomly assigned to the 
study group or the control group by computer at the admis-
sion station. The reduced amniotic ﬂ  uid volume was assessed 
by the four-quadrant technique, as described previously, 
and expressed as centimeters (AFI less than 5th percentile) 
(Rutherford et al 1987). Ultrasonography was performed for 
fetal anatomic study and fetal weight estimation. AFI was 
conﬁ  rmed by a second examiner using the same color Doppler 
3-Dimension ultrasonography machine as the ﬁ  rst examiner. 
Patients who were diagnosed with fetal anomalities by ultro-
sonography (eg, cardiac anomalies, renal cysts), or who were 
diagnosed with diabetes, were not enrolled in this study.
Maternal blood samples were drawn for routine baseline 
laboratory examination, including hemoglobin, hematocrit, 
platelets, and ﬁ  brinogen concentration, for emergency sur-
gery delivery in case of ineffective treatment. Patients were 
divided into 2 groups: one group of 43 received a daily 
intravenous injection of 30 mL salvia extract, provided from 
inter medicine department, mixed with 5% glucose 500 mL 
over 4–6 hours; a control group 41 received conventional 
treatment of 5% glucose 500 mL only. In addition, 10 mg 
of dexamethasone was given once a day for 3 days to those 
patients in both groups at less than 34 weeks of gestation, 
to promote fetal lung maturity, in case the treatment was 
ineffective and the pregnancy terminated. The AFI was re-
assessed at least twice a week by an ultrasonographist who 
was blinded to the treatment. If the AFI increased to normal 
levels, the patient was discharged and followed up at clinics 
until to delivery. If the AFI remained in the abnormal range, 
the patient treatment was continued until the fetus was viable, 
or until the pregnancy terminated due to unviable fetus ( 24 
gestational weeks). If the AFI decreased sharply, so that 
fetal life was threatened, or labor began, the pregnancy was 
concluded by caesarian section. During therapy, fetal well-
being was monitored by: (1) fetal heart rate with a Doppler 
auscultator every 2 hours; (2) fetal body movement counting 
by the mother 3 times a day for 1 hour each; (3) nonstress test, 
fetal electrocardiogram, vibro-acoustic stimulation test, and 
biophysical proﬁ  le were performed at least twice a week.
If any evidence of harmful effects to the mother or fetus 
were found during treatment, the therapy was stopped and nor-
mal management was used. The study ceased when sufﬁ  cient 
data had been collected for statistical analysis. The revised 
recommendations for improving the quality of reports of paral-
lel group randomized trials were used (Moher et al 2001).
Data analysis
All values were expressed as mean ± SEM. Changes in AFI 
were analyzed by paired t test. Statistical signiﬁ  cance was 
set at p   0.05. Assumptions made at the start of the study 
were: (1) that the estimated variance of the paired differences 
was 25%; (2) the certainty that the difference detected was 
at the 0.05 level and was not because of chance (eg, signiﬁ  -
cance level or α = 0.05); (3) the test power is 0.8 (β = 0.80). 
Therefore, 16 patients were needed in this study for paired 
t test; 32 patients were needed for two samples comparison. 
The government or patients paid for all costs depending on 
their medicare policy.
Results
Forty-three pregnant women were enrolled in the salvia proto-
col, and 41 patients in the control group. Mean age of women 
was 28.5 ± 2.3 years (range 21–39 years) (Table 1). Most 
patients (80/84 = 91%) were primigravida. Mean gestational 
age was 32.0 ± 3.5 weeks (range 23–36 weeks). At admission, 
mean AFI was 4.9 ± 2.3 cm (range 1.0–7.9 cm).
Table 1 The clinical characteristics and the results of treatment 
with salvia and the control (mean ± SD or CI 95%)
  Salvia group  Control group  P
Maternal ages (year old)  28.3 ± 2.2  28.5 ± 2.3  NS
  [23.9, 32.7]  [23.9, 33.1] 
Gestational age (weeks)  32.0 ± 3.5  31.1 ± 3.7  NS
  [25.0, 39.0]  [23.7, 38.5] 
Amniotic ﬂ  uid index (cm)
Pretreatment 4.9  ± 2.3* 5.1  ± 2.1  NS
  [1.3, 10.5]  [0.9, 9.3] 
Post-treatment 7.1  ± 2.4  5.5 ± 3.1  S
  [2.3, 11.9]  [0, 11.7] 
Duration of therapy (days)  7.2 ± 2.7  6.9 ± 3.8  NS
 [1.8,  12.6]  [0.14.5] 
Increased velocity (cm/day)  0.18 ± 0.06  0.05 ± 0.02  S
  [0.02, 0.30]  [0.01, 0.09] 
Absolute efﬁ  cacy rate  70(30/43)%  24.4(10/44)%  S
Relative efﬁ  cacy rate  84(36/43)%  36.6(15/41)%  S
Notes: In the salvia group, the amniotic ﬂ  uid index was signiﬁ  cantly increased post-
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After a mean of 7.2 ± 2.7 days’ therapy, ranging from 3 to 
18 days, the AFI increased signiﬁ  cantly to a mean of 7.1 ± 2.4 
cm, ranging from 0 to 10.2 cm (paired t = 3.62, p   0.005). 
The AFI increased by a mean of 0.18 ± 0.06 cm/day. Thirteen 
patients failed to respond to therapy. Among these patients, 
6 showed no signiﬁ  cant increase in AFI, but maintained 
the pretreatment level. Six patients showed a decrease in 
AFI after treatment, and were delivered by caesarean sec-
tion. They had viable infants. One of the 13 patients had an 
inviable fetus and determined of pregnancy at 23 weeks of 
gestation, due to an extremely low ﬂ  uid level. The absolute 
(increased ﬂ  uid) effective rate of salvia was approximately 
70%. The relative (though AFI did not increase, it was 
not easy to maintain pretreatment level due to insufﬁ  cient 
placenta function) effective rate of salvia was 84%. The 
patients showed no side effects. There was no drop out due 
to adverse effects during the clinical trial. The details of the 
control group are set out in Table 1.
Discussion
The results of this clinical trial demonstrate that administration 
of salvia can increase the level of amniotic ﬂ  uid in general, 
and improve the fetal survival environment without maternal 
side effects. The salvia treatment of oligohydramnios has 
never been reported in English. In China, and other countries, 
salvia has been used as therapy for cardiovascular disease, 
chronic renal insufﬁ  ciency, and intrahepatic cholestasis for at 
least 30 years (Fugh-Berman 2000; Kuang et al 2005; Adams 
2006). According to traditional Chinese medicine theory, the 
decrease in urine volume can be attributed to insufﬁ  cient blood 
ﬂ  ow to the kidneys, due to reduced blood volume and blood 
stasis. Urine volume is an important resource of ﬂ  uids during 
pregnancy. Many animal experiments and clinical phase I to 
phase III trials have demonstrated that salvia can activate blood 
circulation and remove blood stasis. Salvia includes many 
active compounds, including magnesium lithospermate A, B, 
C, D, E, F, G, H, I. Previously published research has shown 
approximately 25 kinds of effects of these compounds, includ-
ing magnesium lithospermate, dipotassium lithospermate, 
sodium rosmarinate and potassium danshensu, dipotassium 
isolithospermate B and magnesium salvianolate G. The most 
important of these is magnesium lithospermate B, a tetramer of 
caffeic acid, which is a most powerful efﬁ  cacious compound. 
Figure 1 shows chromatograms of standard mixtures (Xu 
et al 2007). The product here is similar to the standard with 
95.0% to 99.9% and good reproducibility and stability (Xu 
et al 2007). They can ameliorate renal ischemia and improve 
blood circulation and microcirculation in the kidney, thereby 
enhancing the glomerular ﬁ  ltration rate and increasing urine 
(Yokozawa et al 1989; Sun et al 2005).
In pregnant women with oligohydramnios, plasma vis-
cosity and coagulation parameters were signiﬁ  cantly higher 
before onset (Battaglia et al 1995). In the oligohydramnios 
placenta, there exist platelet and ﬁ  brin aggregates and throm-
bosis of the fetal vessels, suggesting that a hypercoagulative 
state and hyperﬁ  brinolysis might affect the microcirculation 
and result in microthrombis, obliteration or sclerosis in the 
small arteries and arteries of the tertiary villi of the placental 
cotyledon (Redline et al 1995). Salvia treatment can regulate 
capillary tension and improve hemorrheological properties, 
by affecting the activity of ﬁ  brinolysis and suppressing 
platelet aggregation, reducing blood viscosity and improving 
microcirculation. In this way, the fetus can gain sufﬁ  cient 
blood from the placenta and excrete urine normally, leading 
to a gradual increase in amniotic ﬂ  uid. As we know, fetal 
urine production is the major source of amniotic ﬂ  uid at 
the second and third trimesters. However, there is no effec-
tive treatment for a low ﬂ  uid level, if the placenta has been 
severely changed pathologically, such as by extreme ﬁ  brin 
formation, calciﬁ  cation, infarction or embolism.
In conclusion, salvia therapy oligohydramnios is a pri-
mary study. The potential beneﬁ  ts and its detailed mecha-
nisms need further in-depth study at multiple centers, based 
on large samples and case-controlled design. This treatment 
is an exciting ﬁ  nding for clinical practice.
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